Revisions to Schedule. InterMune and Abbott currently anticipate that pilot scale/clinical development and validation supplies shall be delivered in accordance with the schedule included in the Proposal. In the event that InterMune communicates to Abbott a need to change such schedule, InterMune and Abbott shall then develop jointly and agree mutually to a revised pilot scale and clinical development schedule. In the event that there is a change in the pilot scale and clinical development schedule that has not been communicated by InterMune to Abbott [*] the parties shall mutually agree to [*] such schedule.
Appears in 2 contracts
Sources: Development and Supply Agreement (Intermune Inc), Development and Supply Agreement (Targanta Therapeutics Corp.)